Inovio Pharmaceuticals (INO) Receives a Buy from Oppenheimer
In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Inovio Pharmaceuticals, with a price target of $13.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Singh is ranked #2884 out of 10072 analysts.
Currently, the analyst consensus on Inovio Pharmaceuticals is a Strong Buy with an average price target of $6.96.
Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $45.5 billion. In comparison, last year the company had a GAAP net loss of $25.17 billion
Read More on INO:
Disclaimer & DisclosureReport an Issue
- Inovio Pharmaceuticals Reports Q3 2025 Financial Results
- Inovio announces common stock offering, no amount given
- Inovio reports Q3 EPS (87c), consensus (48c)
- Options Volatility and Implied Earnings Moves Today, November 10, 2025
- Options Volatility and Implied Earnings Moves This Week, November 10 – November 14, 2025
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.